Case CCC researchers awarded R01 grant from National Institutes of Health
 |
|
|
Richard Padgett
|
|
|
|
Jaroslaw Maciejewski
|
Jaroslaw Maciejewski, MD and Richard Padgett, PhD to test the hypothesis that alterations in the pattern of splicing of target genes play a major role in the establishment or progression of myelodysplastic syndromes (MDS). Maciejewski is
Associate Director for the Lerner Research Institute and Co-Leader of the Hematopoietic and Immune Cancer Biology Program at the Case Comprehensive Cancer Center, and Chair of
Translational Hematology and Oncology Research at the Cleveland Clinic, and Padgett is
Professor of Cellular and Molecular Medicine at the Cleveland Clinic.
Through this work, the researchers aim to further clarify the role of spliceosomal factor mutations and deletions, commonly identified in myeloid malignancies, in the pathogenesis of these diseases through the identification of their effects on mRNA splicing in vivo and in vitro.
more>
|
Jain elected to National Academy of Medicine
|
|
|
Mukesh Jain
|
Mukesh Jain, MD, Case Comprehensive Cancer Center, Chief Scientific Officer, University Hospitals Harrington Discovery Institute, was elected to the National Academy of Medicine this week. Jain is also Chief Scientific Officer, University Hospitals Health System, Chief Research Officer, University Hospitals Harrington Heart & Vascular Institute; the Ellery Sedgwick Jr. Chair & Distinguished Scientist; Director, Case Cardiovascular Research Institute at Case Western Reserve University; and Professor of Medicine, Case Western Reserve University School of Medicine.
Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current active members through a selective process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health.
|
NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
The National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the data upon which the NCCN Guidelines® are based, and quality initiatives in oncology. Topics change annually but focus on the major cancers and
supportive care areas.
The Annual Conference General Session begins on Thursday, March 23 at 8:00 AM and concludes on Saturday evening, March 25. This year's agenda will include more than 25 educational sessions featuring the latest advances in oncology care, plus interactive patient case studies & roundtable discussions.
This conference (with the exception of the NCCN Roundtable Discussions) will be designated for AMA PRA Category 1 Credit™ for physicians and certified for credit for nurses and pharmacists.
Registration Waiver/Discounts for NCCN Member Institutions
Registration fee is waived for NCCN Member Institution junior faculty (with a title of Assistant Professor or below). NCCN also extends a 50% discount off the registration fee to staff employed at NCCN Member Institutions. Interested individuals should e-mail Liz Rieder at rieder@nccn.org to learn more about how to apply for these discounts.
Call For Abstracts
The NCCN fifth annual General Poster Session will take place during the NCCN 22nd Annual Conference. Submissions will be accepted from academic institutions, teaching and community hospitals, or industry. Both NCCN and non-NCCN institutions may participate. Research may fall into one of the general categories below:
- Clinical Oncology (all phases)
- Pre-Clinical Oncology
- Epidemiology/Risks
- Correlative/Genomic
- Best Practices in Implementation and Use of Clinical Practice Guidelines
- Quality Improvement
- Outcomes and Health Services Research
- BIOinformatics/Information Technology Sciences
Abstracts are due on Sunday, November 6, 2016.
|
| Joe Biden talks Cancer Moonshot at Cleveland Clinic innovation summit
The Plain Dealer - Oct 24, 2016
Vice President Joe Biden opened this year's
Cleveland Clinic medical innovation summit with a talk about what he deemed "the only bipartisan thing left in the United States of America"-- the fight against cancer.
Speaking about his Cancer Moonshot initiative, launched in January, Biden told a roomful of doctors, healthcare executives and entrepreneurs that for millions of people across the country affected by cancer, this work is urgent.
"They're not asking to live, they're not asking to be cured," he said. "They're asking for one more moment, and it matters. It matters a lot. Every damn moment counts. And every moment we delay matters."
|
| Making Promises We Cannot Keep
New York Times - Oct 20, 2016
Author Dr. Mikkael Sekeres is director of the leukemia program at the Cleveland Clinic, and Deputy Associate Director for Clinical Research and Director, Clinical Trials for the Case Comprehensive Cancer Center.
|
Image Guided Cancer Specialist Medical doctor, board-certified radiologist and researcher
Jason Williams
, MD, has a new solution to the spiraling costs of cancer treatments: Inject the immunotherapy drugs directly into the cancerous tumor after using image-guided cryoablation..."Biologically, the idea makes sense, because intentionally leaving dead tissue for the body to dispose of naturally is a way to potentially immunize against cancer cells," says tumor immunology and immunotherapy researcher Alex Y. Huang, MD, PhD, Co-Leader, Hematopoioetic and Immune Cancer Biology Program at the Case Comprehensive Cancer Center, associate professor, department of pediatrics at Case Western Reserve University School of Medicine, and clinical fellowship director, division of pediatric hematology/oncology at University Hospitals Cleveland Medical Center/Rainbow Babies & Children's Hospital. "Cryoablation uses cold temperature to induce necrotic cell death, which is a signal for the immune system to wake up. The dead tumor proteins will be seen as foreign by the immune system, which will attack the cancer."
|
Limited Submission: National Comprehensive Cancer Network- NCCN Foundation 2017 Young Investigator Award
Through its
Young Investigator Award (YIA) Program the NCCN Foundation invites proposals from young investigators with innovative ideas and an interest in improving the quality, effectiveness, and efficiency of care provided to cancer patients. A primary focus of the NCCN Foundation YIA is to identify and fund top investigators in the early stages of their careers, interested in participating and contributing to cancer care research and/or elucidating how the NCCN Guidelines are implemented in practice. The NCCN Foundation also recognizes the growing need for evidence-based research in the areas of clinical treatment and management (including new diagnostics and molecular markers), health systems and delivery of care, quality of life for cancer patients, and patient education.
Eligibility Criteria
The award is open to physicians, scientists, nurses and others working in an oncology laboratory, clinical research or clinical setting, or cancer control program in one of NCCN's 27 Member Institutions (CWRU, UH, Cleveland Clinic), who:
- Have a first full-time appointment as an Assistant Professor, Instructor, or an equivalent level, and
- Are MDs, PhDs or, for nurses and others, have an advanced degree.
Nomination Process
Each NCCN Member Institution can nominate up to TWO applicants who may submit research applications.
To be considered for the nomination, submit a letter of interest to
mary.wright@UHhospitals.org
and cc Neal Meropol (
neal.meropol@case.edu
) and Matt Kalaycio (
kalaycm@ccf.org
) by Friday, November 11. LOI should be no more than one-half page, and include applicant name, title, phone, email, study title, brief background, and aims.
Deadlines
Internal Deadline: Friday, November 11 at 5p ET
Nomination Deadline: Friday, November 18 at 5p ET
Application Deadline: Friday, January 16, 2017 at 5p ET
|
Request for Proposals for Case CCC Funding for Pilot/Phase I Clinical Trials
Deadline: Open
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for
Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions.
The proposals are being accepted on a rolling basis subject to availability of funds.
Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office,
katarzyna.karelus@case.edu, 216.844.4176.
|
NIH BULLETIN- Notices and Funding Opportunities
|
|
|
FOLLOW US
|
|
Wed, Oct 26
Hematology and Oncology Division Research Conference Curriculum
Series
Afshin Dowlati, MD
Professor, Div. of Hematology and Oncology
CWRU/UH
"Linda K. Arena Endowed Scholarship Award:
Genomic and clinical markers predictive for outcomes in lung cancer"
8a Lerner B-151
Pathobiology Seminar Series
James Shorter, PhD
Associate Professor, Biochemistry and Biophysics
University of Pennsylvania,
"Protein disaggregase modalities for neurodegenerative disease"
11:30a NA1-139
CDDRCC Seminar
Massarat Zutshi, MD
Department of Colorectal Surgery
Cleveland Clinic
12p NA1-142 Cleveland Clinic
Genomic Medicine Institute
Brittany Psensky, MS & Linford Williams, MS
Licensed Genetic Counselors, Genomic Medicine Institute
Cleveland Clinic
"Genetics 101: Genetic variation & risk assessment"
Q1-300 Cleveland Clinic
|
|
Thurs, Oct 27
Neurosciences Seminar
James Shorter
University of Pennsylvania
"Protein disaggregase modalities to counter neurodegenerative disease"
12:10p BRB 105
Molecular Biology and Microbiology Seminar
Tomoaki Ogino, PhD
Assistant Professor, Molecular Biology & Microbiology
CWRU
1p W203 (Rottman Seminar Room)
Stem Cell Biology Seminar
Junghyup Suh, PhD
Research Scientist, Piscower Institute for Learning and Memory, MIT
"Molecular and circuit basis of awake hippocampal replay"
1p NE1-205 Cleveland Clinic
Case CCC Clinical Research Retreat
5:30-7:30p Cleveland Clinic R3-002/003
|
|
Fri, Oct 28
8a Breen Conf Rm
TCI Grand Rounds
8a R3/002-003 Cleveland Clinic
Cellular and Molecular Medicine Guest Speaker
Jordan Beach, PhD
National Institute of Health, National Heart, Lung, and Blood Institute
"Exploring myosin 2 filament composition and assembly dynamics with super-resolution microscopy"
10a NC1-202 Cleveland Clinic
Cancer Center Seminar Series
Jinming Gao, PhD
Professor, Oncology and Pharmacology
University of Texas Southwestern Medical Center
Adjunct Professor, Chemistry and Bioengineering
University of Texas at Dallas
"pH transistor nanomedicine for cancer sugery and immunotherapy"
12p BRB 105
Cancer Center Research in Progress
Bryan Benson
MD, PhD Candidate,
Huang/Ransohoff labs, Pathology
CWRU
"Using microfluidics to study the leukocyte adhesion cascade"
4p WRB 3-136
|
|
Mon, Oct 31
Cancer Center Research Chalk Talk
1p WRB 3-136
DPB Seminar
David M. Jameson, PhD
Professor, Cell and Molecular Biology
University of Hawai'i at Manoa
"Through a glass, darkly - looking at protein interactions in and out of cells"
|
|
Tues, Nov 1
Department of Pathobiology
Aaron Petrey, PhD
Postdoctoral Research Fellow, de la Motte Lab, Lerner Research Institute, Cleveland Clinic
"Platelet-hyaluronan interactions as regulators of inflammation and thrombosis"
11:30a NC1-202 Cleveland Clinic
Cancer Biology Seminar
Arishya Sharma, PhD
Research Fellow, Almasan Lab, Cancer Biology
Cleveland Clinic
"Loss of autophagy in prostate cancer uncovers the role of USP14 in the NHEJ DNA damage repair"
2p NE1-202 Cleveland Clinic
|
|
Wed, Nov 2
HemOnc Division Conference
8a Lerner B-151
Immunology Seminar Series
Julien Audrey
Runge Lab, Immunology, Cleveland Clinic
and
Xing Chen
Li Lab, Immunology, Cleveland Clinic
12p NC1-202
CDDRCC Seminar
Mahmoud Ghannoum, PhD, EMBA
Professor, Dermatology
CWRU
12p WRB 1-413
|
|
Thurs, Nov 3
Clinical Research Education Session
8-11:15a WRB 1-413
Neurosciences Seminar
Kate Barald, PhD
University of Michigan
12:10p BRB 105
Molecular Biology and Microbiology Seminar
Saba Valadkhan, MD, PhD
Assistant Professor, Biochemistry, CWRU
"Insights into regulation of HIV latency and reactivation from global gene expression studies"
and
Lalith Gunawardane
Assistant Professor, Biochemistry, CWRU
1p W203 (Rottman Seminar Room)
|
|
Fri, Nov 4
8a Breen Conf Rm
Cellular and Molecular Medicine
Maurizio Pacifici, PhD
Children's Hospital of Philadelphia Translational Research Program in Pediatric Orthopaedics, Division of Orthopaedic Surgery
"Insights into fibrodysplasia ossificans progressiva pathogenesis and identification of a possible therapeutic treatment"
10a NC1-202 Cleveland Clinic
Cancer Center Seminar Series
12p BRB 105
Cancer Center Research in Progress
Benjamin Bryson
Graduate Student, Pathology, Cancer Biology Training Program, Jackson Lab
CWRU
"Oncostatin M induces epithelial-mesenchymal transition and stem cell properties in senescent human mammary epithelial cells"
4p WRB 3-136
|
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
Case Comprehensive Cancer Center Clinical Research Retreat
Oct 27
5:30-7:30p Cleveland Clinic R3-002/003
Details & Registration
16th Annual Multidisciplinary Genitourinary Oncology Course
Nov 10
InterContinental Hotel
NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
Mar 23-25, 2017
|
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Application Deadline:
Nov 15
LOI Deadline:
Feb 1, 2017
Deadline: Open
Deadline: Open
Deadline: Open
|
|
 |
|
